HHHeine Hansen

Heine Hansen

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Heine Hansen has a total of 18 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Abelard’s Ontology of Forms: Some New Evidence from theNominalesand theAlbricani

    by Heine Hansen

    This article concerns existents as a contentious issue in contemporary Abelardian scholarship. More precisely, it concerns the ontological standing of forms in Abelard’s metaphysics. Take, for example, the apple on my desk. What ontological standing does its redness have? Is it an actual entity over and above the apple or is it in some sense “reducible” to it? Abelard, famously, was a nominalist, so the question is not about some purported universal redness. Rather, it is about the particular redness of the particular apple on my desk. The issue is contentious in that the best current accounts of Abelard’s metaphysics disagree strongly about how to answer this question. Here, rather than focusing on Abelard’s own writings – which so far have yielded no definitive answer – I will consider some anonymously transmitted and mainly unedited logical texts from the twelfth century and show how his contemporaries understood Abelard’s view and how the followers of his philosophical nemesis, Alberic of Paris, reacted to it.

  • Introduction: Special Issue on the Twelfth-Century Logical Schools

    by John Marenbon, Heine Hansen

    This special issue grew out of a small conference The Known & the Unknown: Exploring Twelfth-Century Philosophy, which was funded by the Carlsberg Foundation, hosted by the Saxo Institute, and held at the University of Copenhagen in April 2018. Its central topic was the many, mostly unexplored, commentaries on Aristotle, Boethius, and Porphyry that constitute the key textual evidence for a fascinating phenomenon that, although it played a pivotal role in the philosophical revival of Western Europe, remains frustratingly underexplored to this day: the logical schools of the twelfth century. The present introduction has two parts. In the first part, John Marenbon lays out the background to this special issue of Vivarium as a whole, explaining both what the philosophical project pursued by twelfth-century logicians was and how, and how far, the historical project of understanding it has progressed over the last two hundred years. In the second part, Heine Hansen briefly presents the issue and its contents.


  • This Woman Is a Father? The Albricani on a Puzzle about Relations

    by Heine Hansen

    Medieval philosophers had a predilection for using the correlative pair father and son as an illustrative example in their discussions of relations. The use of this example has sometimes led to charges of confusion on the grounds that fatherhood and sonship are not proper converses. The present article shows how a group of twelfth-century philosophers from the milieu around the logician Alberic of Paris handled the problems arising from the use of this illustrative example which they had inherited from their ancient and late-ancient predecessors.


  • Open Access

    Efficacy of low‐dose topotecan in second‐line treatment for patients with epithelial ovarian carcinoma

    by Bo Gronlund, Heine H. Hansen, Claus Høgdall, Svend A. Engelholm

    BACKGROUND: The high incidence of dose‐limiting myelosuppresion using the U.S. Food and Drug Administration‐approved topotecan dose of 1.5 mg/m2 for 5 days every 3 weeks may have limited its utility in the treatment of patients with epithelial ovarian carcinoma. The objective of the study was to evaluate the treatment results and toxicity of a low‐dose topotecan regimen as second‐line treatment for patients with epithelial ovarian carcinoma.METHODS: A retrospective analysis was conducted of 203 consecutive patients with primary epithelial ovarian carcinoma who were referred to the Finsen Center during the period from June, 1996 to June, 2000. Eligibility criteria included histopathologically documented, International Federation of Gynecology and Obstetrics (FIGO) Stage IC–IV epithelial ovarian carcinoma; first‐line treatment with paclitaxel and a platinum compound; and second‐line treatment with topotecan (1.0 mg/m2 intravenously for 5 days every 3 weeks). Efficacy and toxicity were compared with published results from pivotal trials using the approved dose of topotecan of 1.5 mg/m2 for the same indication.RESULTS: A total of 56 patients received second‐line treatment with the reduced‐dose topotecan regimen because of refractory, persistent, or recurrent disease. In the subgroup of patients with platinum‐resistant and paclitaxel‐resistant disease (n = 43 patients), the response rate of 11.6% (95% confidence interval [95%CI], 3.9–25.1%) was similar to the response rate of 12.4% (95%CI, 6.9–19.9%) in a pivotal trial using standard‐dose topotecan. In patients with platinum‐resistant and paclitaxel‐resistant disease, the median progression free survival and overall survival from the first day of second‐line topotecan treatment were 2.7 months (range, 0.7–19.5 months) and 6.0 months (range, 1.0–32.8 months), respectively. In a multivariate Cox analysis, the initial performance status (0 vs. 1–2; P = 0.040; hazard ratio [HR], 2.05) and the performance status at the time of second‐line treatment (0 vs. 1–2; P < 0.001; HR, 4.50) were identified as independent prognostic factors for overall survival from the start of second‐line treatment. Grade 4 neutropenia was noted in only 5.1% of reduced‐dose topotecan cycles (95%CI, 2.8–8.4%) compared with 33% and 57% of standard‐dose cycles in pivotal studies.CONCLUSIONS: Topotecan at a dose of 1.0 mg/m2 has similar efficacy based on response rate and lower toxicity compared with the approved schedule of 1.5 mg/m2 for 5 days every 3 weeks in second‐line treatment for patients with platinum‐resistant and paclitaxel‐resistant epithelial ovarian carcinoma. However, a comparison of different topotecan doses and schedules preferably should be made in a randomized setting in well‐characterized populations with regard to established prognostic factors. Cancer 2002;95:1656–62. © 2002 American Cancer Society.DOI 10.1002/cncr.10838


  • Open Access

    A dose escalating study of topotecan preceding cisplatin in previously untreated patients with small-cell lung cancer

    by M. Sorensen, P. B. Jensen, J. Herrstedt, F. R. Hirsch, H. H. Hansen


  • Open Access

    Paclitaxel, gemcitabine, and cisplatin in non-resectable non-small-cell lung cancer

    by J. B. Sørensen, L. E. Stenbygaard, P. Dombernowsky, H. H. Hansen